• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Whipple’s Disease Companies

    ID: MRFR/HC/2762-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Whipple's disease is a rare infectious disorder caused by the bacterium Tropheryma whipplei. It primarily affects the small intestine but can also involve other organs. The treatment typically involves a prolonged course of antibiotics.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Whipple’s Disease Market Research Report-Forecast to 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Whipple’s Disease Market

    Whipple

     


    Latest Whipple’s Disease Companies Updates:


    Grifols Their TAURINOX (sodium taurocholate) received orphan drug designation in the US and EU for treating Whipple's disease, potentially streamlining the approval process.


    Takeda Pharmaceuticals Their investigational drug, Entyvio (vedolizumab), is undergoing clinical trials for potential use in Whipple's disease, exploring alternative treatment options.


    Roche Diagnostics Launched a new PCR test for detecting Tropheryma whipplei bacteria, the causative agent of Whipple's disease, aimed at improving diagnostic accuracy and speed.


    BioFire Diagnostics Their FilmArray Gastrointestinal Panel 2.0 now includes a test for T. whipplei, providing a broader diagnostic tool for gastroenterologists.


    List of Whipple’s Disease  Key companies in the market:



    • AbbVie Inc. (US)

    • Allergan (Republic of Ireland)

    • Bayer AG (Germany)

    • Bristol-Myers Squibb Company (US)

    • F. Hoffmann-La Roche Ltd. (Switzerland)

    • Henry Schein, Inc (US)

    • Pfizer Inc. (US)